Answer ALS Launches AI Collaboration for ALS Drug Discovery

Answer ALS has launched the Louisiana AI Drug Development Infrastructure for ALS (LADDIA), a collaborative initiative aimed at accelerating AI-powered drug discovery for ALS and other neurodegenerative diseases. This effort involves partnerships with GATC Health, Pennington Biomedical Research Center, and Tulane University, announced in a press release.

The initiative, supported by the State of Louisiana, aims to position the state as a leader in AI and biomedical discovery. It will roll out in two phases: the first focuses on building a collaborative foundation and preparing infrastructure, while the second activates this foundation to advance collaborative projects and optimize AI models.

Dr. Jeffrey Keller of Pennington Biomedical and Dr. Aron Culotta of Tulane will lead the effort, utilizing the Neuromine Data Portal, the largest open-access ALS dataset, to identify therapeutic targets. GATC Health will leverage its AI platform to identify druggable ALS targets, sharing findings with the research community to facilitate therapeutic development.